| Literature DB >> 32705188 |
Mayya P Razgonova1, Alexander M Zakharenko1, Kirill S Golokhvast1, Maria Thanasoula2, Evangelia Sarandi2, Konstantinos Nikolouzakis3, Persefoni Fragkiadaki3, Dimitris Tsoukalas2, Demetrios A Spandidos4, Aristidis Tsatsakis3.
Abstract
The current review focuses on the connection of telomerase and telomeres with aging. In this review, we describe the changes in telomerase and telomere length (TEL) during development, their role in carcinogenesis processes, and the consequences of reduced telomerase activity. More specifically, the connection of TEL in peripheral blood cells with the development of aging‑associated diseases is discussed. The review provides systematic data on the role of telomerase in mitochondria, the biology of telomeres in stem cells, as well as the consequences of the forced expression of telomerase (telomerization) in human cells. Additionally, it presents the effects of chronic stress exposure on telomerase activity, the effect of TEL on fertility, and the effect of nutraceutical supplements on TEL. Finally, a comparative review of the chronographic theory of aging, presented by Olovnikov is provided based on currently available scientific research on telomere, telomerase activity, and the nature of aging by multicellular organisms.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32705188 PMCID: PMC7411297 DOI: 10.3892/mmr.2020.11274
Source DB: PubMed Journal: Mol Med Rep ISSN: 1791-2997 Impact factor: 2.952
Figure 1.Schematic representation of the interaction of the telomeric complex (comprised of TRF1, TRF2) with a part of telomeric DNA. Protein components include p95, p23 and ТР1 proteins, as well as the catalytic subunit hTERT, which performs the synthesis of telomeric repeats. Moreover, tankyrase PARP is depicted to also interact with the telomeric complex. TRF, telomeric repeat binding factor; hTERT, human telomerase reverse transcriptase; PARP, poly (ADP)-ribose polymerase.
Telomerase activity in autoimmune diseases.
| No. | Disease | Telomerase activity in autoimmune disease | (Refs.) |
|---|---|---|---|
| 1 | Rheumatoid arthritis | The telomerase activity level in synovial infiltrating lymphocytes was significantly correlated with the intensity of synovial lining hyperplasia, microvessel proliferation, lymphocyte infiltration, and percentage of synovial cells positive for proliferating cell nuclear antigen in rheumatoid synovium | Yudoh |
| Activated lymphocytes with high telomerase activity distribute systemically through the circulation and contribute disease activity in connective tissue disease. The stimulatory effect of estrogens on telomerase activity and female predominance in connective tissue disease may contribute to high telomerase activity in these pathologies. | Hiyama and Hiyama ( | ||
| Telomerase activity in lymphoid cells of lymphoid organs is higher than in peripheral blood. | Hiyama and Hiyama ( | ||
| Highest hTERT values were observed in Rheumatoid arthritis group (21.24±28.54). hTERT values were significantly higher than the healthy control group (7.62±4.21) (P<0.05). | Tarhan | ||
| Lack of telomerase activity leads to excessive loss of T cells, which limits the possibility of homeostatic control of naive T-lymphocytes. | Fujii | ||
| T cells as a result of repeated stimulations correspond to decreasing peaks of mRNA and hTERT induction, compared with the first highest peak. | Valensuela and Effros ( | ||
| 2 | Systemic lupus erythematosus | High telomerase activity in peripheral blood mononuclear cells. | Katayama and Kohriyama ( |
| Significant correlation between telomerase activity and disease severity. With an exacerbation of the disease, telomerase activity in mononuclear cells of peripheral blood is significantly higher than in the control group. | Klapper | ||
| There was no evidence of telomere shortening in lymphocytes and no correlation between telomerase activity and telomere length. | Klapper | ||
| The activity of telomerase in the cells is sufficient to compensate for the shortening of telomeres, and thus prevent the accelerated aging of the immune system of patients. | Klapper | ||
| 3 | Systemic sclerosis | The most interesting finding was very low PBC hTERT levels in the Systemic sclerosis group. If really there is a tendency for lower telomerase activity in Systemic sclerosis, this may be related with the telomere shortening reported by Artlett | Tarhan |
| T lymphocyte homeostasis is significantly impaired. | Hug | ||
| Thymic T cell production was estimated by measuring TCR excision circles (TRECs) as a traceable molecular marker in recent thymic emigrants. an impaired thymic export function and, as a consequence, altered ability to maintain T cell homeostasis and immune tolerance may play an important pathogenic role in relapsing remitting Multiplex Sclerosis. | Hug | ||
| T cells as a result of repeated stimulations correspond to decreasing peaks of mRNA and hTERT induction, compared with the first highest peak. | Valensuela and Effros ( | ||
| 4 | Atopic dermatitis and psoriasis | Telomerase activity in the affected areas of the skin is significantly higher than in intact skin and is associated with proliferative activity of the cell. | Jang |
| Lymphocytes that infiltrate the epidermis are not responsible for the level of telomerase, since it does not correlate with the number of these lymphocytes. | Ogoshi | ||
| The level of telomerase activity in skin diseases that are not malignant is much lower than in malignant tumors. | Taylor | ||
| A high level of telomerase activity in peripheral blood mononuclear cells compared to donors. | Wu | ||
| 5 | The length of telomeres in blood cells progressively decreases by 216 base pairs in addition to the age loss of 36 base pairs per year. | Brümmendorf | |
| The telomere reduction and short cell life can be explained by the presence of mutations associated with this disease in the hTR and hTERT genes. | Ly ( | ||
| Most patients carrying these mutations are insensitive to immunosuppressive therapy. | Ly ( | ||
| Among patients with polymorphisms in the TERT gene, the telomere length was within 90% of the values of healthy donors. | Yamaguchi |